Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event
Advancing to IND-enabling studies with multiple drug candidates
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
The combined company will be able to better serve both our global and regional customers with local production
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Subscribe To Our Newsletter & Stay Updated